- Low
- 52,000
- Average
- 114,309
- Median
- 113,880
- High
- 202,010
Biomarin Pharmaceutical Salary
44
88
85
Related Biomarin Pharmaceutical Salary
- CVS Salary
- Mayo Clinic Salary
- Cerner Salary
- Medtronic Salary
- Amgen Salary
- International Baccalaureate Organization Salary
- Medpace Salary
- Cepheid Salary
- Clinicas Del Camino Real Salary
- Fidessa Salary
- Iridium Consulting Salary
- Mindex Technologies Salary
- Heartland Payment Systems Salary
- Yakima Valley Farm Workers Clinic Salary
Calculate how much you could earn
It's FREE. Based on your input and our analysis. How we do it?
All fields are required for calculation accuracy.
- We will send you an email to access your personalized report.
- We won’t share your email address
Real Jobs Salary - Salary List- 8.5 million company & government reported salaries with date & location
- Salary calculator rank & calculate your salary
- 151 million W-2s pay scale statistics in U.S.
- Salary Map helps you navigate location based salary information
- State & City Salary provides wage data by metropolitan areas
- Company Salaries has salaries data from over 200,000 companies
Guyp Salary Biomarin Pharmaceutical Jobs
| See more Biomarin Pharmaceutical Jobs» | |
| Search All Jobs | |
Patents information
1719
All Patents
353
Grant Patents
1068
Patents Pending
356
Patents Families
More Recent
-
US11918633B2Compositions of prokaryotic phenylalanine ammonia-lyase and methods of treating adolescent subjects
-
US20240035013A1COMPOSITIONS OF PROKARYOTIC PHENYLALANINE AMMONIA-LYASE VARIANTS AND METHODS OF USING COMPOSITIONS THEREOF
-
US20240058423A1Adeno-Associated Virus Factor VIII Vectors, Associated Viral Particles and Therapeutic Formulations Comprising the Same
- View More »
Biomarin Pharmaceutica... Information
- BioMarin Pharmaceutical
- Industry: BioTech/Drugs
- City: Novato, CA
- BioMarin Pharmaceutical Inc. develops enzyme therapies to treat debilitating, life-threatening genetic diseases and other indications. The Company has two enzyme replacement therapies in clinical trials and recently filed an application to enter a third enzyme into the clinic. Aldurazyme, a joint venture with Genzyme General, is an enzyme replacement therapy in a 45 patient, double-blind, placebo-controlled Phase III clinical trial to treat Mucopolysaccharidosis I (MPS I), a life-threatening genetic disease. On July 20, 2001, the Company completed the 24 week treatment stage of its Phase I clinical trial ofrhASB, an enzyme replacement therapy for the treatment of MPS VI,
